-$0.28 expected earnings per share for Enlivex Therapeutics Ltd. (NASDAQ: ENLV) this quarter

Analysts expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is posting earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Zero analysts released earnings estimates for Enlivex Therapeutics. Enlivex Therapeutics reported earnings of ($0.43) per share in the same quarter last year, suggesting a positive year-over-year growth rate of 34.9%. The company is expected to release its next quarterly earnings report on Friday, April 29.

According to Zacks, analysts expect Enlivex Therapeutics to report full year earnings of ($0.86) per share for the current fiscal year. For the next fiscal year, analysts expect the company to report earnings of ($1.54) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research companies that track Enlivex Therapeutics.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings data on Sunday, November 21. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.21) by $0.02.

The NASDAQ ENLV traded down $0.03 during Friday’s trading, hitting $5.23. 15,344 shares of the company have been traded, compared to its average volume of 61,919. The stock has a market capitalization of $95.77 million, a price-earnings ratio of -5.34 and a beta of 1. ,16. Enlivex Therapeutics has a 12 month minimum of $4.76 and a 12 month maximum of $19.82. The company has a 50-day moving average of $5.71 and a 200-day moving average of $8.09.

Several large investors have recently increased or reduced their stake in ENLV. Marshall Wace LLP purchased a new stake in Enlivex Therapeutics in the fourth quarter for $39,000. Geode Capital Management LLC bought a new position in Enlivex Therapeutics in the third quarter worth $102,000. UBS Group AG increased its stake in Enlivex Therapeutics by 15.2% in the third quarter. UBS Group AG now owns 15,454 shares in the company worth $152,000 after buying an additional 2,034 shares last quarter. Morgan Stanley increased its stake in Enlivex Therapeutics by 453.5% in the first quarter. Morgan Stanley now owns 15,531 shares of the company worth $172,000 after buying an additional 12,725 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Enlivex Therapeutics by 8.3% in the second quarter. Wells Fargo & Company MN now owns 19,491 shares of the company worth $174,000 after purchasing an additional 1,500 shares last quarter. 3.51% of the shares are held by hedge funds and other institutional investors.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is developing a pipeline of autologous and allogeneic drugs for the treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, graft versus host disease resulting from bone marrow transplants, solid organ transplants and a range of autoimmune and inflammatory diseases, such as as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders.

Read more

Get a Free Copy of Zacks Research Report on Enlivex Therapeutics (ENLV)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Enlivex Therapeutics right now?

Before you consider Enlivex Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Enlivex Therapeutics was not on the list.

While Enlivex Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here